• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2020, Vol. 37 ›› Issue (6): 497-504.

• 药物经济学研究 • 上一篇    

雷贝拉唑与奥美拉唑三联疗法治疗胃溃疡的系统综述与成本效果分析

邢影影, 孙琪菲, 檀楠楠, 杨方娜, 牛粉霞, 李勇*   

  1. 中国药科大学国际医药商学院, 江苏 南京 211198
  • 收稿日期:2019-11-28 修回日期:2019-12-13 出版日期:2020-12-28 发布日期:2020-12-28

A Systematic Review and Economic Evaluation of Rabeprazole-based Triple Therapy Versus Omeprazole-based Triple Therapy for Patientswith Gastric Ulcer

  1. China Pharmaceutical University International Pharmaceutical Business School, Jiangsu Nanjing 211198, China
  • Received:2019-11-28 Revised:2019-12-13 Online:2020-12-28 Published:2020-12-28
  • Contact: li yongyong E-mail:lsyg168@163.com

摘要: 目的:通过Meta分析和决策树模型对雷贝拉唑与奥美拉唑三联疗法治疗胃溃疡的有效性、安全性及经济性进行评价,为临床治疗胃溃疡用药提供参考。方法: 通过Meta分析比较两种治疗方案的疗效和安全性,运用决策树模型,对两种治疗方案治疗胃溃疡进行成本效果分析,并进行单因素敏感性分析和概率敏感性分析。结果: Meta分析结果显示,在幽门螺杆菌根除率方面,雷贝拉唑三联疗法优于奥美拉唑三联疗法(RR=1.14,P<0.000 01);在溃疡愈合率方面,雷贝拉唑三联疗法优于奥美拉唑三联疗法(OR=2.58,P=0.01);在临床安全性方面,两种方案具有显著性差异,在治疗过程中雷贝拉唑三联疗法的不良反应发生率低于奥美拉唑三联疗法(OR=0.61,P=0.01),雷贝拉唑三联疗法具有更好的安全性。药物经济学评价结果表明,相比于奥美拉唑三联疗法,雷贝拉唑三联疗法的ICER值为1 732.78元,敏感性分析结果与成本效果分析结果基本一致。结论: 雷贝拉唑三联疗法治疗胃溃疡的疗效优于奥美拉唑三联疗法,但相比于奥美拉唑三联疗法,雷贝拉唑三联疗法的ICER值过高,因此奥美拉唑三联疗法治疗胃溃疡更具有成本-效果优势。

关键词: font-size:medium, ">雷贝拉唑;奥美拉唑;胃溃疡;Meta分析;成本效果分析

Abstract: Objective: To evaluate the efficacy, safety and economy of rabeprazole and omeprazole triple therapy in the treatment of gastric ulcer by meta-analysis and decision tree model, and provide reference for clinical treatment of gastric ulcer. Methods: The efficacy and safety of the two treatment regimens were analyzed and compared by meta analysis. The decision tree model was used to analyze the cost effects of the two treatment regimens for the treatment of gastric ulcer, and single factor sensitivity analysis and probability sensitivity analysis were performed.Results: Meta-analysis showed that rabeprazole triple therapy was superior to omeprazole triple therapy (RR=1.14, P<0.000 01) in terms of H. pylori eradication rate; rabeprazole triplet in ulcer healing rate The therapy was superior to omeprazole triple therapy (OR=2.58, P=0.01); in terms of clinical safety, there were significant differences between the two regimens, and the incidence of adverse reactions of rabeprazole triple therapy was lower during the treatment. Omeprazole triple therapy (OR=0.61, P=0.01), rabeprazole triple therapy has better safety. The results of pharmacoeconomic evaluation showed that the ICER value of rabeprazole triple therapy was 1 732.78 yuan compared with the omeprazole triple therapy. The sensitivity analysis results were basically consistent with the cost effect analysis results, indicating that the cost effect analysis results were more stable. Conclusion: Rabeprazole triple therapy is superior to omeprazole triple therapy in the treatment of gastric ulcer, but the ICER value of rabeprazole triple therapy is too high compared to omeprazole triple therapy, so omeprazole Triple therapy for gastric ulcers has a cost-effective advantage.
  

Key words: font-size:medium, ">Rabeprazole; Omeprazole; Gastric ulcer; Meta-analysis; Cost effectiveness analysis

中图分类号: